대한핵의학회지 (The Korean Journal of Nuclear Medicine)

대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

방사면역치료용 $^{188}Re$ 표지 항체의 안정성과 안정제의 효과

Stability of $^{188}Re$ Labeled Antibody for Radioimmunotherapy and the Effect of Stabilizing Agents

  • 장영수 (서울대학교 의과대학 핵의학교실) ;
  • 김보광 (서울대학교 의과대학 핵의학교실) ;
  • 정재민 (서울대학교 의과대학 핵의학교실) ;
  • 정준기 (서울대학교 의과대학 핵의학교실) ;
  • 이승진 (이화여자대학교 약학대학) ;
  • 이동수 (서울대학교 의과대학 핵의학교실) ;
  • 이명철 (서울대학교 의과대학 핵의학교실)
  • Chang, Young-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Kim, Bo-Kwang (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Jeong, Jae-Min (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Chung, June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee, Seung-Jin (College of Pharmacy, Ewha Woman University) ;
  • Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee, Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • 발행 : 2002.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 베타입자 방출 핵종을 표지한 항체를 임상적으로 이용하기 위해서는 높은 비방사능을 가지는 것이 중요하다. $^{188}W/^{188}Re$ 발생기를 사용하여 쉽게 얻을 수 있는 무담체 $^{188}Re$은 이런 목적에 이상적인 방사성 핵종이다. 하지만 높은 비방사능의 $^{188}Re$이 표지된 항체는 높은 베타 에너지(2.1 MeV)로 인한 불안정성이 문제가 된다. 우리는 $^{188}Re$이 표지된 항체의 안정성을 확보하기 위해 몇 가지 안정제가 미치는 영향에 대해서 조사하였다. 대상 및 방법: 환원시킨 단일클론항체(CEA79.4)에 stannous tartrate와 발생기에서 용출한 $^{188}Re-perrhenate$를 넣어 실온에서 2시간 반응시켰다. 각각의 방사화학적순도는 크로마토그라피를 써서 확인하였다. 표지된 항체에 사람 혈청 알부민(HSA)을 첨가(최종농도 2%)하고 ascorbic acid, ethanol, Tween 80 존재 하에서의 안정성을 각각 조사하였다. 결과: 표지된 항체의 비방사능은 $1.25{\sim}4.77MBq/{\mu}g$, 표지 효율은 $88{\pm}4%\;(n=12)$였다. 안정제로 ascorbic acid, ethanol, Tween 80을 첨가하였을 때 $N_2$ 존재 하에서 모든 경우에 10시간까지 안정하였으나, 공기와 접촉 시 10시간 후에 방사화학적순도는 각각 처음의 100, 45, 36%가 되었다. 과산화레늄(perrhenate)과 $^{188}Re-tartrate$의 증가가 주된 요인이었으며 콜로이드 형성은 모든 경우에 큰 영향을 끼치지 않았다. Ascorbic acid 첨가는 공기 중에서 perrhenate의 형성을 줄임으로서 항체의 안정성에 가장 많이 기여하였다. 결론: 높은 비방사능의 $^{188}Re$이 표지된 항체는 공기 중에 노출되었을 때 불안정하였으며, ascorbic acid 첨가시 안정성을 향상시킬 수 있었다.

Purpose: For clinical application of beta-emitter labeled antibody, high specific activity is imporiant. Carrier-free $^{188}Re$ from $^{188}W/^{188}Re$ generator is an ideal radionuclide for this purpose. However, low stability of $^{188}Re$ labeled antibody, especially in high specific activity, due to radiolytic decomposition by high energy (2.1 MeV) beta ray was problem. We studied the stability of $^{188}Re$ labeled antibody, and stabilizing effect of several stabilizers. Materials and Methods: Pre-reduced monoclonal antibody (CEA79.4) was labeled with $^{188}Re$ by incubating with generator-eluted $^{188}Re-perrhenate$ in the presence of stannous tartrate for 2 hr at room temperature. Radiochemical purity of each preparation was determined by chromatography. Human serum albumin was added to the labeled antibodies (2%). Stability of $^{188}Re-CEA79.4$ was investigated in the presence of ascorbic acid, ethanol, of Tween 80 as stabilizing agents. Results: Labeling efficiencies were $88{\pm}4%\;(n=12)$. Specific activities of $1.25{\sim}4.77MBq/{\mu}g$ were obtained. If stored after purging with $N_2$, all the preparations were stable for 10 hr. However, stability decreased in the presence of air. Perrhenate and $^{188}Re-tartrate$ was major impurity in declined preparation. colloid-formation was not a significant problem in all cases. Addition of ascorbic acid stabilized the labeled antibodies either under $N_2$ or under air by reducing the formation of perrhenate. Conclusion: High specific activity $^{188}Re$ labeled antibody is unstable, especially, in the presence of oxygen. Addition of ascorbic acid increased the stability.

키워드

참고문헌

  1. Eckelman WC, Paik CH, Reba RC. Radiolabelingof antibodies. Cancer Res 1980;40:3036-42.
  2. Griffiths GL, Goldenberg DM, Diril H, HansenHJ. Technetium-99m, rhenium-186, and rhenium188direct-labeled antibodies. Cancer 1994;73:761-8.
  3. Wilder RB, DeNardo GL, DeNardo SJ.Radioimmunotherapy: recent results and futuredirections. J cu« Oneal 1996;14: 1383-400.
  4. Chung JK, Yeo J, Lee DS, Park S, Lee MC,Kim BK, et al. Bone marrow scintigraphy usingtechnetium-99m-antigranulocyte antibody in hematologicdisorders. J Nucl Med 1996;37:978-82.
  5. Higuchi T, Inoue T, Sarwar M, Oriuchi N,Karasawa M, Naruse T, et al. Tc-99m- labelledchimeric human/mouse antigranulocyte antibodybone marrow scintigraphy: a preliminary clincalstudy. Nucl Med Comm 1998;19:463-74.
  6. Mausner LF, Srivastava SC. Selection ofradionuclides for radioimmunotherapy. Med Phys1993;20:503-9.
  7. John E, Thakur TJ, DeFulvio J, McDevitt MR,Damjanov 1. Rhenium-186-1abeled monoclonalantibodies for radioimmunotherapy: preparationand evaluation. J Nucl Med 1993;34:260-7.
  8. Rhodes BA, Lambert CR, Marek MJ Knapp FF,Harvey EB. Re-188 labelled antibodies. ApplRadiat Isot 1996;47:7-14.
  9. Iznaga-Escobar N. Re-188 direct labeling ofmonoclonal antibodies for radioimmunotherapyof solid tumors: biodistribution, normal organdosimetry, and toxicology. Nucl Med Bioi1998;25:441-7.
  10. Lee J, Lee DS, Kim YJ, Chang YS, Jeong JM,Shin SA, et al. Labeling and biodistribution ofRe-188-DTPA. Korean J Nucl Med 1997;31:42732.
  11. Kim YJ, Jeong JM, Chang YS, Lee DS, ChungJK, Lee MC, et al. Study of Re-188(V)-DMSAfor treatment of cancer: radiolabeling andbiodistribution. Korean J Nucl Med 1998;32:81-8.
  12. Kim YJ, Jeong JM, Chang YS, Lee YJ, Lee DS,Chung JK, et al. Preparation and biodistributionof Re-188 sulfur colloid. Korean J Nucl Med1998;32:298-304.
  13. Chang YS, Jeong JM, Lee DS, Chung JK, LeeMC. Quality control of tungsten-188/rhenium188generator. Korean J Nucl Med 1998;32:42532.
  14. Chang YS, Jeong JM, Kim BK, Cho JR, LeeDS, Chung J-K, et al. Effect of carrier onlabeling and biodistribution of Re-188-hydroxyethylenediphosphonate. Korean J Nucl Med2000;34:344-52.
  15. Mather SJ, Ellison D. Reduction-mediatedtechnetium-99m labeling of monoclonalantibodies. J Nucl Med 1990;31:692-7.
  16. John E, Thakur ML, Wilder S, Alauddin MM,Epstein AL. Technetium-99m-labeled monoclonalantibodies: influence of technetium-99m bindingsites. J Nucl Med 1994;35:876-81.
  17. Griffiths GL, Goldenberg DM, Knapp FF,Callahan AP, Chang CH, Hansen HJ. Directradiolabeling of monoclonal antibodies withgenerator-produced rhenium-188 for radioimmunotherapy:labeling and animal biodistributionstudies. Cancer Res 1991;51:4594-602.
  18. Normando IE. Direct radiolabeling of monoclonalantibodies with rhenium-188 for radioimmunotherapyof solid tumors-a review of radiolabelingcharacteristics, quality control and in vitrostability studies. Appl Rad Isotope 2001;54:399-406.
  19. Hong MK, Jeong JM, Chung J-K, Choi SR,Kim CK, Lee YJ, et al. 99mTc labelling kitpreparation and characteristics of anti- NCA-95monoclonal antibody. Korean J Nucl Med1996;30:541-7.
  20. Hong MK, Jeong JM, Yeo JS, Kim KM, ChangYS, Lee YJ, et al. In vitro properties andbiodistribution of Tc-99m and Re-188 labeledmonoclonal antibody CEA 79.4. Korean J NuclMed 1998;32:516-24.
  21. Salako QA, O'Donnell RT, DeNardo SJ. Effectsof radiolysis on yttrium-90-labeled Lym-Iantibody preparations. J Nucl Med 1998;39:66770.
  22. Wahl RL, Wissing J, Rosario RD, Zasadny KR.Inhibition of autoradiolysis of radiolabeled. monoclonal antibodies by cryopreservation. JNucl Med 1990;31:84-9.
  23. Chakrabarti MC, Le N, Paik CH, De Graff WG,Carrasquillo JA. Prevention of radiolysis ofmonoclonal antibody during labeling. J NuclMed 1996;37:1384-8.
  24. Hnatowich DJ, Virzi F, Winnard P, Fogarasi M,Rusckowski M. Investigations of ascorbate fordirect labeling of antibodies with technetium99m.J Nucl Med 1994;35:127-34.
  25. Seymour CB, Mothersill C, Moriarty MJ, TiptonKF. The effect of ethanol on the radiationresponse of CHO-KI cells. Br J Raiol 1987;60(714):577-81.